欢迎访问药物流行病学杂志网站！

设为首页加入收藏

国家科技部中国科技论文统计源期刊

中国科技核心期刊

WHO西太平洋地区医学索引(WPRIM)收录期刊

湖北优秀期刊

《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>

复方血栓通胶囊治疗急性中心性浆液性脉络膜视网膜病变临床观察

Clinical Observation of Compound Xueshuantong Capsule for Acute Central Serous Chorioretinopathy

DOI：

中文关键词: 急性中心性浆液性脉络膜视网膜病变复方血栓通胶囊临床疗效安全性

英文关键词:Acute central serous chorioretinopathy Compound Xueshuantong capsule Clinical efficacy Safety

基金项目:

作者	单位
李育红^① 李晖^② 廖秋霞^①	荆门市第一人民医院①药学部；②眼科（湖北荆门 448000）

摘要点击次数: 816

全文下载次数: 866

中文摘要:

摘要目的：观察复方血栓通胶囊治疗急性中心性浆液性脉络膜视网膜病变（CSC）的临床疗效和安全性。方法：急性CSC患者83例（83眼）随机分为观察组42例（42眼）和对照组41例（41眼）。对照组给予口服维生素E软胶囊0.1g，qd，维生素C片0.2g，tid，维生素B1片10mg，tid；，观察组在对照组治疗基础上加用复方血栓通胶囊1.5g，po，tid。持续服用2个月，比较两组临床疗效、治愈时间、视力恢复时间、药品不良反应以及治疗前后视力、光学相干断层扫描技术（OCT）检查结果变化；随访3个月，比较两组复发率。结果：观察组总有效率为90.5%，显著高于对照组的26.8%（P<0.05）。观察组治疗1，4，8周后视力均明显优于对照组（P<0.05），治愈时间、视力恢复时间也显著短于对照组（P<0.05）。治疗后，两组黄斑中心区直径1mm范围的厚度、黄斑中心区直径6mm的平均厚度和黄斑中心区直径6mm的总体积均较治疗前显著降低（P<0.05），且观察组明显低于对照组（P<0.05）。随访3个月，观察组复发率明显低于对照组（P<0.05）。两组患者均未发生药品不良反应。结论：复方血栓通胶囊治疗急性CSC能显著提高疗效，且安全性较好。

英文摘要:

ABSTRACT Objective:To investigate the efficacy and safety of Compound Xueshuantong capsule for acute central serous chorioretinopathy (CSC). Methods:Totally 83 patients (83 eyes) who suffered acute CSC were divided into two groups randomly. The treatment group included 42 cases (42 eyes), and the control group 41 cases (41 eyes). The control group was given Vitamin E soft capsules 0.1g, qd, Vitamin C tablets 0.2g, tid, and Vitamin B1 tablets 10mg, tid. Based the above treatment, treatment group was given Compound Xueshuantong capsule 1.5g, tid additionally. The treatment courses were two months. The curative effect, healing time, visual recovery time, ADR and the OCT results of two groups were compared. The recurrence rate of two groups were compared at 3 months follow up.Results:After treatment, the total effective rate in treatment group was 90.5%, which was significantly higher than 26.8% in the control group(P<0.05). After 1, 4, 8 weeks treatment, the vision was increased significantly in treatment group（P<0.05）. Healing time, visual recovery time in treatment goup was significantly less than those in the control group（P<0.05）. Macular center thickness of 1 mm diameter range, the average thickness of the macular area of 6 mm diameter and the diameter and the central area and the total macular volume of both group were significantly lower than before（P<0.05）, and the treatment group was much lower than the control group. At 3 months follow up, the recurrence rate of treatment group was significantly lower than the control group（P<0.05）. No significant ADR was observed in two groups.Conclusion: Compound Xueshuantong capsule could significantly improve the efficacy in the treatment of acute central serous chorioretinopathy, and it had good safety.

查看全文查看/发表评论下载PDF阅读器

关闭